Xinhong Lim

Xinhong Lim, Ph.D. has had a varied work experience. From 2015 to present, they have been Managing Director, Member of the Investment Committee, Assistant Managing Director, Director, and Venture Principal at Vickers Venture Partners. In 2020, they became Chief Strategy Officer (CSO) and Board Member at RWDC Industries, and Board Member at EMERGEX VACCINES HOLDING LIMITED. In 2019, they were a Board Observer at Lumitron Technologies Inc. and Aardvark Therapeutics. In 2018, they were an Adjunct Assistant Professor and Principal Investigator at the Skin Research Institute of Singapore. In 2017, they were a Board Observer at SiSaf Ltd. From 2001 to present, they have been an Artillery Officer and Battalion Tactics Trainer in the Singapore Armed Forces reserves. In 2015, they were an Adjunct Assistant Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. In 2022, they will become a Board Observer at Biosplice Therapeutics.

Xinhong Lim, Ph.D. obtained a BS in Biochemistry from the University of Wisconsin-Madison in 2003-2006. Xinhong then attended Stanford University School of Medicine where they obtained their Ph.D. in Developmental Biology in 2007-2013. In 2010, they attended The Jackson Laboratories for the 19th Annual Short Course on Experimental Models of Human Cancer. In 2012, they attended Stanford University Graduate School of Business for the Program in Innovation and Entrepreneurship in Entrepreneurship/Entrepreneurial Studies. In 2014, they attended Cold Spring Harbor Laboratory for Mouse Development, Stem Cells and Cancer. In 2016, they attended the Experimental Therapeutics Centre, Singapore for Drug Discovery and Development.